Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis.

Article Details

Citation

Copy to clipboard

Moreland LW

Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis.

Cleve Clin J Med. 1999 Jun;66(6):367-74.

PubMed ID

10375846 [ View in PubMed

]

Abstract

Infliximab and etanercept, both approved by the FDA in 1998, are examples of a new class of disease-modifying antirheumatic drugs that interfere with the action of tumor necrosis factor alpha, one of the key cytokines that promote inflammation. Infliximab is approved for Crohn disease and etanercept for rheumatoid arthritis. Both show promise in treating rheumatoid arthritis, although the long-term risks and benefits of these drugs are not yet known.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Etanercept	Tumor necrosis factor	Protein	Humans	Yes	Inhibitor Antibody	Details